You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Weighted VZV seroprevalence rates stratified by age in varicella-unvaccinated children 1–17 years of age, Germany

From: Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany

Anti-VZV IgG antibodies tested by ELISA, weighted seroprevalence rate [% (95%CI)] Age in years
1 (n = 374) 2 (n = 503) 3 (n = 569) 4 (n = 644) 5 (n = 662) 6 (n = 765) 7 (n = 800) 8 (n = 832) 9 (n = 839)
 Positive 12.0 (8.1–17.4) 25.2 (20.8–30.1) 38.4 (33.5–43.5) 60.1 (55.6–64.4) 73.3 (68.9–77.2) 85.7 (82.4–88.5) 87.3 (84.4–89.8) 89.6 (87.2–91.6) 93.2 (90.5–95.1)
 Negative 87.8 (82.4–91.7) 74.4 (69.5–78.8) 60.9 (55.8–65.7) 39.4 (35.1–43.9) 26.2 (22.3–30.6) 14.0 (11.2–17.3) 12.0 (9.6–14.9) 9.4 (7.5–11.7) 6.0 (4.2–8.6)
 Equivocal result 0.2 (0.0–1.5) 0.4 (0.1–1.5) 0.7 (0.2–2.8) 0.5 (0.2–1.5) 0.5 (0.2–1.4) 0.3 (0.1–0.8) 0.6 (0.3–1.6) 1.0 (0.5–2.0) 0.8 (0.4–1.7)
Anti-VZV IgG antibodies tested by ELISA, weighted seroprevalence rate [% (95%CI)] Age in years
10 (n = 808) 11 (n = 861) 12 (n = 808) 13 (n = 830) 14 (n = 814) 15 (n = 794) 16 (n = 712) 17 (n = 662) Total (n = 12,277)
 Positive 94.1 (91.7–95.9) 93.0 (90.5–94.9) 93.7 (91.4–95.5) 94.0 (91.6–95.7) 94.5 (92.6–96.0) 95.4 (93.5–96.8) 96.4 (94.6–97.6) 94.2 (91.8–96.0) 80.3 (79.3–81.3)
 Negative 5.4 (3.8–7.7) 6.6 (4.8–9.0) 5.0 (3.5–7.1) 5.0 (3.5–7.2) 4.5 (3.2–6.3) 3.7 (2.5–5.5) 3.3 (2.1–5.0) 4.3 (2.8–6.6) 18.9 (18.0–19.9)
 Equivocal result 0.5 (0.2–1.2) 0.4 (0.1–1.0) 1.3 (0.7–2.5) 1.0 (0.5–2.3) 1.0 (0.5–1.9) 0.8 (0.4–1.9) 0.4 (0.1–1.2) 1.5 (0.7–2.9) 0.7 (0.6–0.9)
  1. Sera collected 2003–2006, n = 12,277, tested by ELISA